- Expansion marks progress in the development of wearable
biosensing platform to monitor multiple key biomarkers in
real-time
- Study expected to demonstrate the capability of Rockley’s
Bioptx™ biosensing band to monitor and measure multiple biomarkers,
including core body temperature and hydration, more accurately than
other commonly available tools and wrist-worn devices
Rockley Photonics Holdings Limited (NYSE: RKLY) (“Rockley”), a
global leader in photonics-based health monitoring and
communications solutions, today announced the expansion of its
free-living human study to a broader population of participants.
The study will test the capability of its Bioptx™ biosensing band
to remotely monitor and measure key biomarkers including core body
temperature and hydration outside a laboratory setting.
Rockley’s biosensing technology is expected to advance health
and wellness tracking by enabling wearable monitoring devices to
capture critical data of multiple biomarkers more accurately and in
real-time. The study expansion is based on strong initial
free-living human study results that showed Rockley’s technology
provided accurate biomarker measurements. The study is expected to
capture data from 50 subjects and should be completed in the fourth
quarter of 2022.
Results from Rockley’s study are expected to confirm the
accuracy of Rockley’s biosensing technology platform. Potential
important applications for health and wellness include continuous
monitoring of the circadian rhythm, fever detection, fertility
cycle, and sleep patterns.
Accurate measurement of biomarkers such as core body temperature
and hydration are critical in monitoring and tracking basic health
and wellness. Existing wearable devices simply measure skin
temperature, leading to imprecise indications of temperature. And
without a “gold standard” of measurement, determining the hydration
level of a patient is costly and time-consuming. By enabling the
accurate detection of biomarkers from a wearable monitoring device
and tracking them over time, Rockley’s biosensing platform has the
potential to provide real-time insights about a variety of health
conditions and to provide early indications of changes to an
individual’s health.
Dr. Andrew Rickman, chairman and chief executive officer of
Rockley, said: “The expansion of Rockley’s free-living study using
our Bioptx biosensing band brings us closer to advancing healthcare
and wellness monitoring to the next level. Many important
biomarkers like core body temperature are not accurately or
conveniently monitored using existing tools and even the latest
wrist-worn devices, yet they are core vital signs, providing
critical clues to human health. In my own free-living experience
while testing the Bioptx biosensing band over several months, the
solution correctly detected a fever the day before I was impacted
by an illness. I believe that our solution will provide people with
information that will help them live healthier lives and this
free-living study will help us demonstrate the power of our
device.”
More information about Rockley’s digital health monitoring
solution is available here:
https://rockleyphotonics.com/healthcare-sensing
About Rockley Photonics
A global leader in photonics-based health monitoring and
communications solutions, Rockley Photonics is developing a
comprehensive range of photonic integrated circuits and associated
modules, sensors, and full-stack solutions. From next-generation
sensing platforms specifically designed for mobile health
monitoring and machine vision to high-speed, high-volume solutions
for data communications, Rockley is laying the foundation for a new
generation of applications across multiple industries. Rockley
believes that photonics will eventually become as pervasive as
micro-electronics, and it has developed a platform with the power
and flexibility needed to address both mass markets and a wide
variety of vertical applications.
Formed in 2013, Rockley is uniquely positioned to support
hyper-scale manufacturing and address a multitude of high-volume
markets. Rockley has partnered with numerous tier-1 customers
across a diverse range of industries to deliver the complex optical
systems required to bring transformational products to market.
To learn more about Rockley, visit rockleyphotonics.com.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release that are not historical facts
constitute “forward-looking statements” for purposes of the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. These forward-looking statements include statements
regarding Rockley’s future expectations, beliefs, plans,
objectives, and assumptions regarding future events or performance.
The words “accelerate,” “advance,” “anticipate,” “believe,” “can,”
“capability,” “continue,” “could,” “develop,” “enable,” “estimate,”
“eventual,” “expand, “expect,” “focus,” “forward,” “future,”
“goal,” “intend,” “may,” “might,” “opportunity,” “outlook,” “plan,”
“possible,” “position,” “potential,” “predict,” “project,”
“revolutionize,” “seem,” “should,” “trend,” “vision,” “will,”
“would” or other terms that predict or indicate future events,
trends, or expectations, and similar expressions or the negative of
such expressions may identify forward-looking statements, but the
absence of these words or terms does not mean that a statement is
not forward-looking. Forward-looking statements in this press
release include, but are not limited to, statements regarding the
following: (a) our expectations regarding our expanded free-living
study, including expected results and timing; (b) the ability of
our biosensing technology platform to monitor changes to human
cycles such as the circadian rhythm, fever detection, fertility,
and sleep patterns; (c) the ability of our biosensing platform to
provide accurate detection of biomarkers from a wearable monitoring
device and track them over time; (d) the ability of Rockley’s
biosensing platform to provide real-time insights about a variety
of health conditions and to provide early indications of changes to
an individual’s health; (e) our ability to advance healthcare and
wellness monitoring to the next level; (f) our belief that
important biomarkers are not accurately or conveniently monitored
using existing tools and devices; (g) our belief that we are laying
the foundation for a new generation of applications across multiple
industries; (h) the anticipated and potential features, scope,
goals, and benefits of the Company’s platform, products, and
technology; (i) Rockley’s belief that photonics will eventually
become as pervasive as micro-electronics; (j) the ability of our
platform to address both mass markets and a wide variety of
vertical applications; and (k) Rockley’s potential to support
hyper-scale manufacturing, address a multitude of high-volume
markets, and deliver the complex optical systems required to bring
transformational products to market.
Forward-looking statements are subject to several risks,
assumptions, and uncertainties (many of which are beyond Rockley’s
control) that may cause actual results or performance to differ
materially from those expressed or implied by these forward-looking
statements. These risks, assumptions, and uncertainties include,
but are not limited to, the factors described under the heading
“Risk Factors” in our Annual Report on Form 10-K for the year ended
December 31, 2021 and in other documents we file with the
Securities and Exchange Commission. If any of these risks or
uncertainties materialize, or should any of these assumptions prove
incorrect, actual results may differ materially from those
discussed in or implied by these forward-looking statements. There
can be no assurance that future developments affecting Rockley will
be those that have been anticipated. Given these risks and
uncertainties, you should not place undue reliance on these
forward-looking statements. These forward-looking statements speak
only as of the date hereof and Rockley does not intend to update or
revise any forward-looking statements, whether because of new
information, future events, or otherwise, except as required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221006005997/en/
Media Debra Raine Rainemakers Telephone: +1 415-349-7432 Email:
rockleyphotonics@rainemakers.com
Investors Gwyn Lauber Rockley Photonics Telephone: +1
626-995-0001 Email: investors@rockleyphotonics.com
Rockley Photonics (NYSE:RKLY)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025
Rockley Photonics (NYSE:RKLY)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025
